Document is current
Any future updates will be listed below
-
Authors
Yukami, Hiroki
Kawakami, Hisato https://orcid.org/0000-0002-3280-4850
Yamaguchi, Toshifumi
Sakai, Daisuke
Shimokawa, Toshio
Kurokawa, Yukinori
Goto, Masahiro
Satoh, Taroh
- License Information
-
More Information
Article History
Received: 15 April 2023
Accepted: 20 June 2023
First Online: 7 July 2023
Declarations
:
: HY has no competing interests to disclose. HK has received consulting fees from Daiichi-Sankyo Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., Incyte Biosciences Japan, and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co., Ltd.; and research funding from Bristol-Myers Squibb Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd. TY has no competing interests to disclose. DS has received honoraria from Daiichi Sankyo Co. Ltd., and Chugai Pharmaceutical Co., Ltd.; and research funding from Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Taiho Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. TS has no competing interests to disclose. YK has received honoraria from Taiho Pharmaceutical Co. Ltd. and research funding from Taiho Pharmaceutical Co. Ltd. and Yakult Pharmaceutical Industry. MG has no competing interests to disclose. TS has received honoraria from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., and Yakult Pharmaceutical Industry; research funding from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., and Yakult Pharmaceutical Industry.; scholarship donations from Taiho Pharmaceutical Co. Ltd.; and endowed chairs from Ono Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, and Chugai Pharmaceutical Co.
: The study protocol was approved by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) Steering Committee and the Institutional Review Boards of all participating hospitals. The current study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All the patients provided written informed consent prior to initiating chemotherapy.
